483
Kaleido Biosciences, Inc.Kaleido Biosciences, Inc. – FDA 483, Mar 3, 2021
Record Details
An FDA inspection of Kaleido Biosciences, Inc. in Lexington, MA, revealed a critical regulatory violation regarding clinical investigations. The firm conducted two clinical studies involving investigational new drugs without first submitting an Investigational New Drug (IND) application to the FDA. This represents a serious failure to comply with regulatory requirements for human subject protection and drug development oversight.
View Company Profile
ID · 0de44820-fdcf-47c8-bfdf-b6d47b2bc1ad
Other documents for Kaleido Biosciences, Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.